LGVNLongeveron Inc.

Nasdaq longeveron.com


$ 2.54 $ -0.03 (-1.17 %)    

Thursday, 08-Aug-2024 11:57:19 EDT
QQQ $ 446.49 $ 7.83 (1.78 %)
DIA $ 393.25 $ 3.68 (0.94 %)
SPY $ 528.62 $ 4.51 (0.86 %)
TLT $ 95.21 $ -0.75 (-0.79 %)
GLD $ 223.83 $ 1.10 (0.49 %)
$ 2.57
$ 2.59
$ 2.58 x 100
-- x --
$ 2.52 - $ 2.61
$ 0.77 - $ 35.60
856,140
na
16.32M
$ 0.70
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-14-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-13-2022 03-31-2022 10-Q
10 03-11-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-13-2021 06-30-2021 10-Q
13 05-14-2021 03-31-2021 10-Q
14 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 longeveron-has-been-granted-australian-patent-number-2017213812-titled-mesenchymal-stem-cells-as-vaccine-adjuvants-and-methods-for-using-the-same

https://ipsearch.ipaustralia.gov.au/patents/2017213812

 hc-wainwright--co-reiterates-buy-on-longeveron-maintains-10-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Longeveron (NASDAQ:LGVN) with a Buy and maintains $10 price ta...

 why-is-alzheimers-focused-longeveron-stock-trading-higher-on-monday

Longeveron presented promising Phase 2a clinical trial data for Lomecel-B at the AAIC 2024. The trial showed the drug's saf...

Core News & Articles
Market-Moving News for July 29th
07/29/2024 12:22:29

LGVN:  49% | Longeveron Announced Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B In Mild Alzheimer's Di...

 hc-wainwright--co-maintains-buy-on-longeveron-lowers-price-target-to-10

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Longeveron (NASDAQ:LGVN) with a Buy and lowers the price target...

 longeveron-announced-study-results-from-clear-mind-phase-2a-clinical-trial-of-lomecel-b-in-mild-alzheimers-disease--study-meets-its-key-objectives-to-advance-data-supporting-favorable-benefitrisk-profile

- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for...

 why-longeveron-lgvn-shares-are-down-15

Longeveron shares are trading lower by 15.9% during Thursday's session. The company announced a $9.0 million registered dir...

 longeveron-enters-into-agreements-for-issuance-and-sale-of-22m-shares-of-class-a-common-stock-at-4025-per-share-in-registered-direct-offering

Concurrent Private Placement To Issue Unregistered Warrants For 2.2M Shares With $3.90 Exercise Price; Offering Expected To Clo...

Core News & Articles
Market-Moving News for July 17th
07/17/2024 12:10:53

AEHR: 18% | Aehr Test Systems shares are trading higher after the company reported better-than-expected Q4 financial results an...

 longeveron-receives-fda-fast-track-designation-for-lomecel-b-for-mild-alzheimers-disease-second-designation-following-rmat-designation-on-july-9-2024

Phase 2a Data To Be Presented At Alzheimer's Association International Conference; Lomecel-B Is An Allogeneic Investigation...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION